Polycystic Ovarian Syndrome - Pipeline Review, H2 2016

Publisher Name :
Date: 31-Aug-2016
No. of pages: 55

Polycystic Ovarian Syndrome - Pipeline Review, H2 2016

Summary

Global Markets Direct's, ‘Polycystic Ovarian Syndrome - Pipeline Review, H2 2016', provides an overview of the Polycystic Ovarian Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Polycystic Ovarian Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Polycystic Ovarian Syndrome and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Polycystic Ovarian Syndrome

- The report reviews pipeline therapeutics for Polycystic Ovarian Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Polycystic Ovarian Syndrome therapeutics and enlists all their major and minor projects

- The report assesses Polycystic Ovarian Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Polycystic Ovarian Syndrome

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Polycystic Ovarian Syndrome

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Polycystic Ovarian Syndrome pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Polycystic Ovarian Syndrome - Pipeline Review, H2 2016

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Polycystic Ovarian Syndrome Overview 7
Therapeutics Development 8
Pipeline Products for Polycystic Ovarian Syndrome - Overview 8
Pipeline Products for Polycystic Ovarian Syndrome - Comparative Analysis 9
Polycystic Ovarian Syndrome - Therapeutics under Development by Companies 10
Polycystic Ovarian Syndrome - Therapeutics under Investigation by Universities/Institutes 11
Polycystic Ovarian Syndrome - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Unknown Stage Products 15
Polycystic Ovarian Syndrome - Products under Development by Companies 16
Polycystic Ovarian Syndrome - Products under Investigation by Universities/Institutes 17
Polycystic Ovarian Syndrome - Companies Involved in Therapeutics Development 18
Addex Therapeutics Ltd 18
Crinetics Pharmaceuticals, Inc. 19
EffRx Pharmaceuticals S.A. 20
Euroscreen S.A. 21
Merck KGaA 22
Millendo Therapeutics, Inc. 23
Vicore Pharma AB 24
Polycystic Ovarian Syndrome - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
C-21 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
choriogonadotropin alfa - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
ESN-364 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
JDSCR-004 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
KDT-501 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
metformin hydrochloride - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
MLE-4901 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Small Molecule to Antagonize FSH Receptor for Women's Health - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Small Molecules to Inhibit KISS-1R for Polycystic Ovarian Syndrome - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Polycystic Ovarian Syndrome - Dormant Projects 47
Polycystic Ovarian Syndrome - Discontinued Products 48
Polycystic Ovarian Syndrome - Product Development Milestones 49
Featured News & Press Releases 49
Aug 16, 2016: Millendo Therapeutics Announces Initiation of Phase 2b Clinical Trial of MLE4901 in Patients with Polycystic Ovary Syndrome 49
Jul 27, 2016: Millendo Therapeutics Announces Publication of Positive Phase 2a Data for MLE4901 for the Treatment of Polycystic Ovary Syndrome 49
Jul 19, 2016: EUROSCREEN opens US-IND for ESN364 on three Phase II trials 50
Apr 21, 2015: Euroscreen starts in parallel two Phase 2 clinical trials with ESN364 in UF and PCOS patients 50
Dec 08, 2014: Euroscreen Announces Positive Completion of Phase I Trial of ESN364 51
Jun 20, 2014: Euroscreen ESN364 drug candidate presented at the ICE/ENDO Meeting 51
Jun 10, 2014: EffRx Receives U.S. Orphan Drug Designation for EX404 for Treatment of Pediatric Polycystic Ovary Syndrome 51
Dec 18, 2013: Euroscreen Initiates Phase I Clinical Trial For ESN364 52
Oct 01, 2013: EffRx Receives Prestigious EUR 5.9 Million FP7 Research Grant for the Development of EX404 for Polycystic Ovary Syndrome in Paediatric Populations 52
Feb 05, 2013: Euroscreen to present ESN364 drug candidate at the 11th International Symposium on GnRH 53
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 54
Disclaimer 55

List of Tables
Number of Products under Development for Polycystic Ovarian Syndrome, H2 2016 8
Number of Products under Development for Polycystic Ovarian Syndrome - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Comparative Analysis by Unknown Stage Development, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Polycystic Ovarian Syndrome - Pipeline by Addex Therapeutics Ltd, H2 2016 18
Polycystic Ovarian Syndrome - Pipeline by Crinetics Pharmaceuticals, Inc., H2 2016 19
Polycystic Ovarian Syndrome - Pipeline by EffRx Pharmaceuticals S.A., H2 2016 20
Polycystic Ovarian Syndrome - Pipeline by Euroscreen S.A., H2 2016 21
Polycystic Ovarian Syndrome - Pipeline by Merck KGaA, H2 2016 22
Polycystic Ovarian Syndrome - Pipeline by Millendo Therapeutics, Inc., H2 2016 23
Polycystic Ovarian Syndrome - Pipeline by Vicore Pharma AB, H2 2016 24
Assessment by Monotherapy Products, H2 2016 25
Number of Products by Stage and Target, H2 2016 27
Number of Products by Stage and Mechanism of Action, H2 2016 29
Number of Products by Stage and Route of Administration, H2 2016 31
Number of Products by Stage and Molecule Type, H2 2016 33
Polycystic Ovarian Syndrome - Dormant Projects, H2 2016 47
Polycystic Ovarian Syndrome - Discontinued Products, H2 2016 48

List of Figures
Number of Products under Development for Polycystic Ovarian Syndrome, H2 2016 8
Number of Products under Development for Polycystic Ovarian Syndrome - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Products, H2 2016 14
Assessment by Monotherapy Products, H2 2016 25
Number of Products by Targets, H2 2016 26
Number of Products by Stage and Targets, H2 2016 26
Number of Products by Mechanism of Actions, H2 2016 28
Number of Products by Stage and Mechanism of Actions, H2 2016 28
Number of Products by Routes of Administration, H2 2016 30
Number of Products by Stage and Routes of Administration, H2 2016 30
Number of Products by Molecule Types, H2 2016 32
Number of Products by Stage and Molecule Types, H2 2016 32
  • Asia Pacific Makeup Market To Grow Owing To Impactful Promotion And Progress Of Distribution Networks
    The Asia Pacific makeup market is one of the most assorted and active markets in the cosmetics industry throughout the world and is projected to grow at a CAGR of 7.1% between 2013 and 2019. The makeup market in Asia Pacific is assessed to be worth US$22.31 billion by 2019. The world-wide market was at an approximation of US$14.76 [...]
  • Growing Demand in Emergent Markets To Boost Bakery Ingredients Market
    The baking ingredients market is predictable to grow at a CAGR of 5.2% from 2015 to reach an estimated value of US$ 15.19 billion by 2020. Evolving economies throughout the globe have been displaying demand for bakery ingredients at a greater rate in agreement with the economic growth. Numerous companies have been occupied on refining [...]
  • Packaging Sector Driven By Innovation
    The financial development in numerous emerging nations has significantly influenced the progress of quite a lot of sectors, the packaging industry being one of them. The swell in transport undertakings outfitting to a substantial number of industries such as manufacturing, consumer goods, food and beverages, and others rest essentially on sturdy and resilient packaging solutions [...]
  • Global Eyewear Market To Gain From Increased Demand For Disposable Contact Lenses
    The global eyewear market was worth US$ 102.66 billion in 2015 and is predictable to reach US$ 184.03 billion by 2024. The rising population and upsurge in the number of optical disorders are likely to propel the industry in the near future. Moreover, the increasing cognizance amongst people as regards to the prominence of eye [...]
  • Global mHealth Market To Become A Multi-Billion Dollar Industry By 2020
    The mHealth market is in its embryonic stage and is projected to produce substantial profits with amassed awareness level and encouraging regulatory guidelines particular to the quality and practicality of mobile-based medical devices. The global mHealth market is projected to touch US$ 49.12 billion by 2020 rising at a CAGR of 47.6% from 2013 to 2020. Monitoring services [...]
  • Global Menopause Partnering 2010-2017
    Published: 01-Feb-2017        Price: US 1495 Onwards        Pages: 150
    "Delivery of this report will take 1-3 days after purchase." Summary Provides understanding and access to the menopause partnering deals and agreements entered into by the worlds leading healthcare companies. Description The Global Menopause Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies.......
  • Global Contraception Partnering 2010-2017
    Published: 01-Feb-2017        Price: US 1495 Onwards        Pages: 150
    "Delivery of this report will take 1-3 days after purchase." Summary Provides understanding and access to the contraception partnering deals and agreements entered into by the worlds leading healthcare companies. Description The Global Contraception Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare compani......
  • Global Obstetrics Partnering 2010-2017: Deal trends, players and financials
    Published: 01-Feb-2017        Price: US 2995 Onwards        Pages: 200
    "Delivery of this report will take 1-3 days after purchase." Summary Global Obstetrics Partnering 2010-2017: Deal trends, players and financials provides understanding and access to the obstetrics partnering deals and agreements entered into by the worlds leading healthcare companies Description Global Obstetrics Partnering 2010 to 2017 provides the full collection of Obstetrics disease deals signed between the world's ......
  • Global Gynecology Partnering 2010-2017: Deal trends, players and financials
    Published: 01-Feb-2017        Price: US 2995 Onwards        Pages: 300
    "Delivery of this report will take 1-3 days after purchase." Summary The Global Gynecology Partnering 2010-2017: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the gynecology partnering deals and agreements entered into by the worlds leading healthcare companies Description Global Gynecology Partnering 2010-2017: Deal trends, players and financials provides th......
  • Global Assisted Reproductive Technology Market Research Report 2016
    Published: 02-Jan-2017        Price: US 2900 Onwards        Pages: 103
    Notes: Production, means the output of Assisted Reproductive Technology Revenue, means the sales value of Assisted Reproductive Technology This report studies Assisted Reproductive Technology in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Irvine Scientific - Origio a/s - ......
  • Minerva-35 -Drug Insights, 2017
    Published: 01-Jan-2017        Price: US 1000 Onwards        Pages: 35
    DelveInsight Drug Report, "Minerva-35- Drug Insights, 2017" highlights the Minerva-35 marketed details, pipeline status and the Global API Manufacturers along with the location. The DelveInsight's report covers the Global Market Assessment of the Minerva-35 covering the total sales estimation and also provides the Minerva-35 sales performance during the historical period and forecast period to 2018. DelveInsight's Report also covers the detailed clinical assessment of Minerva-35, patents informa......
  • Postmenopausal Vaginal Atrophy  - Epidemiology Forecast To 2023
    Published: 01-Jan-2017        Price: US 2750 Onwards        Pages: 60
    DelveInsight "Postmenopausal Vaginal Atrophy - Epidemiology Forecast To 2023" provides an overview of the epidemiology trends of Postmenopausal Vaginal Atrophy in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Postmenopausal Vaginal Atrophy prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on......
  • Nexplanon -Drug Insights, 2017
    Published: 01-Jan-2017        Price: US 1000 Onwards        Pages: 35
    DelveInsight Drug Report, "Nexplanon- Drug Insights, 2017" highlights the Nexplanon marketed details, pipeline status and the Global API Manufacturers along with the location. The DelveInsight's report covers the Global Market Assessment of the Nexplanon covering the total sales estimation and also provides the Nexplanon sales performance during the historical period and forecast period to 2018. DelveInsight's Report also covers the detailed clinical assessment of Nexplanon, patents information ......
  • Vaginal Atrophy (Atrophic Vaginitis)-API Insights, 2017
    Published: 01-Jan-2017        Price: US 1250 Onwards        Pages: 60
    The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs